Bradykinin B2 Receptor Antagonists

Bradykinin B2 Receptor Antagonist

Angioedemas, Hereditary

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">FIRAZYR (icatibant) is a synthetic decapeptide with five non-proteinogenic amino acids.  The chemical structure of icatibant acetate is presented in Figure 1.</p><p><span class="Bold">Figure 1 Chemical Structure</span></p><p><img alt="Figure 1" src="firazyr-01.jpg"/></p><div class="Section" data-sectioncode="42229-5"><a name="section-10.1"></a><p></p><p class="First">Chemical name: D-Arginyl-L-arginyl-L-prolyl-L[(4R)-4-hydroxyprolyl]-glycyl-L[3-(2-thienyl)alanyl]-L-seryl-D-(1,2,3,4-tetrahydroisoquinolin-3-ylcarbonyl)-L[(3aS,7aS)-octahydroindol-2-ylcarbonyl]-L-arginine, acetate salt</p><p>FIRAZYR is provided as a sterile, isotonic, and buffered solution of icatibant acetate in a single-dose, prefilled syringe for subcutaneous administration.  Each mL of the solution contains 10 mg of icatibant (free base) which is equivalent to 11.38 mg of icatibant acetate.  Each prefilled syringe delivers 3 mL of solution equivalent to a 30 mg icatibant dose.  The solution is clear and colorless.</p><p>The solution also contains sodium chloride (isotonicity reagent), glacial acetic acid (pH adjuster), sodium hydroxide (pH adjuster) and water for injection with a pH of approximately 5.5.  The solution does not contain preservatives.</p></div><div class="Section" data-sectioncode="42229-5"><a name="section-10.2"></a><p></p><p class="First">Pharmacological class: Icatibant is a bradykinin B2 receptor antagonist.</p></div></section>

Firazyr

icatibant

3 ML icatibant 10 MG/ML Prefilled Syringe

3 ML icatibant 10 MG/ML Prefilled Syringe [Firazyr]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Firazyr is employed to address hereditary angioedema attacks, an immune system disorder, in adults.

It's important to note that Firazyr does not provide a cure for hereditary angioedema.

Report Adverse Event

Prescribing Information

Medication Guide 

Prescribing Information - Spanish

Medication Guide - Spanish

Submit MSL Request

Pharmacy List 

Online Sample Form 

Coverage Authorization Request 

Coverage Authorization Appeal 

 Formulary Exception Letter 

Letter of Medical Necessity 

Letter of Intent To Treat 

One Path Enrollment Form 

Enroll in Patient Savings Program 

Other HCP Resouces 

Patient Brochure 

About Firazyr

Taking Firazyr

Side Effects 

FAQs: HAE

One Path Support Program 

Patient Resources 

Instructions For Use: Hereditary Angioedema